All News

D&D Reports 62.5% MASH Resolution With Zabopegdutide

By Sandy Martin•November 20, 2026

D&D Pharmatech says 62.5% of patients receiving zabopegdutide had MASH resolution on 48-week liver biopsy. The result puts a closely watched GLP-1-based approach to metabolic liver disease in focus.

D&D Pharmatech says its experimental drug zabopegdutide produced resolution of metabolic dysfunction-associated steatohepatitis, or MASH, in 62.5% of patients assessed by liver biopsy after 48 weeks. A report on the biopsy findings also says the company is discussing licensing opportunities with large pharmaceutical groups.

The percentage is a company-reported clinical result. No peer-reviewed primary paper or public trial-registry or regulatory results record was identified for the 48-week claim, so the finding cannot yet be independently verified or fully interpreted.

Even at this preliminary stage, the result is relevant to metabolic-liver drug development. MASH is characterized by excess liver fat accompanied by inflammation and liver-cell injury, and it can progress to fibrosis and more serious liver disease. Zabopegdutide is described as a GLP-1-based candidate, placing it within a broader effort to use metabolic therapies to address the drivers of liver injury.

Reading the 62.5% result correctly

In a MASH trial, histologic resolution generally means that a follow-up biopsy no longer meets the pathological criteria for steatohepatitis. That is a meaningful drug-development endpoint, but it is not interchangeable with fibrosis improvement, which is typically evaluated separately.

The percentage alone does not reveal the size or certainty of the treatment effect. Interpretation depends on the number of patients who started treatment, how many had usable follow-up biopsies, the dose or doses studied, whether the trial was randomized and placebo-controlled, and how missing biopsy data were handled. The publicly available account does not establish these details, nor does it provide a statistical comparison or a full safety analysis.

The denominator is particularly important. A response rate from a small group can change substantially with the outcome of one or two patients, whereas a similar percentage in a larger randomized population would carry greater evidential weight. Baseline disease severity also matters because patients with different degrees of inflammation or fibrosis may not have the same probability of histologic improvement.

Why a biopsy-based endpoint carries weight

Liver biopsy remains central to trials seeking to demonstrate that a therapy resolves MASH. A 2025 review of biopsy use in clinical studies describes it as the confirmed method for assessing treatment efficacy, while also noting that the tissue collected represents only a small portion of the liver and that the procedure can cause complications.

Histology allows pathologists to examine liver fat, inflammation, cellular injury and fibrosis directly. That makes biopsy-based data more informative for this endpoint than a change in body weight or a non-invasive liver marker alone. It also explains why a 48-week biopsy result can attract attention from potential development partners.

Biopsy is not a perfectly uniform measurement, however. Disease can be distributed unevenly within the liver, and small tissue samples may not capture that variation. Tissue collection, sample adequacy, pathology methods and whether slides are read centrally can all affect confidence in the result. A biopsy endpoint therefore raises the relevance of the finding without removing the need to examine how the trial was conducted.

GLP-1 evidence supports the approach, not this molecule

Zabopegdutide’s GLP-1-based design has a plausible metabolic rationale. Drugs acting through GLP-1 pathways can reduce food intake and improve glucose regulation; resulting changes in body weight, insulin sensitivity and metabolic stress may in turn reduce factors contributing to liver-fat accumulation and injury.

There is also randomized human evidence that this broader drug class can affect MASH histology. A 2025 meta-analysis of randomized controlled trials examined FDA-approved GLP-1 receptor agonists in adults with biopsy-confirmed MASH. Across the included trials, treatment was associated with greater odds of MASH resolution without worsening fibrosis at 18 months than placebo.

That finding supports the therapeutic strategy, but it does not verify zabopegdutide’s result. The meta-analysis did not establish outcomes for this candidate, and results cannot be transferred automatically between drugs with different pharmacology, doses, treatment durations and study populations. Its 18-month evidence also should not be treated as a direct benchmark for a separately reported 48-week result.

Placebo response and biopsy quality shape the number

MASH trials can record substantial histologic improvement among placebo recipients. A 2026 review of published trials found placebo response rates ranging from 2% to 34%. That variability can reflect natural changes in disease, behavioral support provided during trials, differences between enrolled populations and aspects of biopsy assessment.

This makes the comparator essential. A 62.5% response rate may represent a strong treatment signal, but its magnitude cannot be calculated without knowing the response in a comparable control group. The absolute difference between groups, confidence intervals and prespecified statistical analysis would be more informative than the treatment-group percentage in isolation.

The same review found that studies have not consistently reported biopsy-quality details such as needle gauge, tissue-core length and the number of portal tracts in a sample. It also noted that direct evidence connecting these measures with randomized histologic response rates remains limited. These issues do not negate the reported zabopegdutide result; they define the information needed to judge its robustness.

From a headline result to decision-grade evidence

Licensing discussions indicate commercial interest, but they do not independently validate efficacy. Potential partners will be able to examine information that is not yet public, including the protocol, patient-level results, pathology procedures, adverse events and the consistency of responses across doses and baseline disease stages.

For clinicians and health-literate readers, the immediate significance is developmental rather than practice-changing. Zabopegdutide has generated a potentially important biopsy signal in patients with MASH, against a backdrop of randomized evidence that GLP-1 therapies can improve liver histology. It has not yet produced publicly accessible, peer-reviewed evidence sufficient to establish the size or reliability of its own effect.

The most informative next step would be a complete trial presentation or publication reporting the sample size, comparator, analysis population, biopsy standards, fibrosis findings and safety data. If those details show a controlled and statistically credible benefit, the reported 62.5% resolution rate would become meaningful molecule-specific evidence rather than an encouraging standalone percentage.